Howard W. Lightfoot

On-target mutations confer resistance to WRN helicase inhibitors in Microsatellite Unstable Cancer Cells.

This study identifies on-target WRN mutations as resistance mechanisms in MSI cancer cells to WRN helicase inhibitors and suggests combination therapies to prevent resistance.

Pan-cancer proteomic map of 949 human cell lines reveals principles of cancer vulnerabilities

The paper presents a pan-cancer proteomic map of 949 cell lines, revealing protein-specific biomarkers of cancer vulnerabilities and showing proteomic data's superior predictive power for drug response.

Integrated cross-study datasets of genetic dependencies in cancer

The paper integrates two large CRISPR-Cas9 screens to improve the detection of gene dependencies and cancer vulnerabilities by addressing biases and batch effects.

Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens

This study integrates drug sensitivity data with CRISPR screens to identify drug mechanisms and biomarkers for cancer therapy.